NVO Quote, Financials, Valuation and Earnings

Amgen has a net margin of 38.28% compared to Novo Nordisk AS's net margin of 33.28%. Novo Nordisk AS's return on equity of 88.95% beat Amgen's return on equity of 65.35%.

Novo Nordisk AS has a consensus price target of $117.14, signalling upside risk potential of 36.78%. On the other hand Amgen has an analysts' consensus of $319.35 which suggests that it could grow by 20.87%. Given that Novo Nordisk AS has higher upside potential than Amgen, analysts believe Novo Nordisk AS is more attractive than Amgen.

Novo Nordisk AS has a beta of 0.447, which suggesting that the stock is 55.342% less volatile than S&P 500. In comparison Amgen has a beta of 0.561, suggesting its less volatile than the S&P 500 by 43.928%.

Novo Nordisk AS has a quarterly dividend of $0.52 per share corresponding to a yield of 1.69%. Amgen offers a yield of 3.41% to investors and pays a quarterly dividend of $2.25 per share. Novo Nordisk AS pays 37.96% of its earnings as a dividend. Amgen pays out 67.83% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Novo Nordisk AS quarterly revenues are $10.5B, which are larger than Amgen quarterly revenues of $8.5B. Novo Nordisk AS's net income of $4B is higher than Amgen's net income of $2.8B. Notably, Novo Nordisk AS's price-to-earnings ratio is 27.75x while Amgen's PE ratio is 33.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 9.72x versus 4.38x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.

Ascendis Pharma AS has a net margin of 38.28% compared to Novo Nordisk AS's net margin of -171.53%. Novo Nordisk AS's return on equity of 88.95% beat Ascendis Pharma AS's return on equity of -880.05%.

Novo Nordisk AS has a consensus price target of $117.14, signalling upside risk potential of 36.78%. On the other hand Ascendis Pharma AS has an analysts' consensus of $191.30 which suggests that it could grow by 42.3%. Given that Ascendis Pharma AS has higher upside potential than Novo Nordisk AS, analysts believe Ascendis Pharma AS is more attractive than Novo Nordisk AS.

Novo Nordisk AS has a beta of 0.447, which suggesting that the stock is 55.342% less volatile than S&P 500. In comparison Ascendis Pharma AS has a beta of 0.649, suggesting its less volatile than the S&P 500 by 35.145%.

Novo Nordisk AS has a quarterly dividend of $0.52 per share corresponding to a yield of 1.69%. Ascendis Pharma AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk AS pays 37.96% of its earnings as a dividend. Ascendis Pharma AS pays out -- of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novo Nordisk AS quarterly revenues are $10.5B, which are larger than Ascendis Pharma AS quarterly revenues of $63.6M. Novo Nordisk AS's net income of $4B is higher than Ascendis Pharma AS's net income of -$109.1M. Notably, Novo Nordisk AS's price-to-earnings ratio is 27.75x while Ascendis Pharma AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 9.72x versus 21.63x for Ascendis Pharma AS. Usually stocks with elevated PS ratios are considered overvalued.

Evaxion Biotech AS has a net margin of 38.28% compared to Novo Nordisk AS's net margin of -64.14%. Novo Nordisk AS's return on equity of 88.95% beat Evaxion Biotech AS's return on equity of --.

Novo Nordisk AS has a consensus price target of $117.14, signalling upside risk potential of 36.78%. On the other hand Evaxion Biotech AS has an analysts' consensus of -- which suggests that it could grow by 1199.16%. Given that Evaxion Biotech AS has higher upside potential than Novo Nordisk AS, analysts believe Evaxion Biotech AS is more attractive than Novo Nordisk AS.

Novo Nordisk AS has a beta of 0.447, which suggesting that the stock is 55.342% less volatile than S&P 500. In comparison Evaxion Biotech AS has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Novo Nordisk AS has a quarterly dividend of $0.52 per share corresponding to a yield of 1.69%. Evaxion Biotech AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk AS pays 37.96% of its earnings as a dividend. Evaxion Biotech AS pays out -- of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novo Nordisk AS quarterly revenues are $10.5B, which are larger than Evaxion Biotech AS quarterly revenues of $3M. Novo Nordisk AS's net income of $4B is higher than Evaxion Biotech AS's net income of -$1.9M. Notably, Novo Nordisk AS's price-to-earnings ratio is 27.75x while Evaxion Biotech AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 9.72x versus 1.23x for Evaxion Biotech AS. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of 38.28% compared to Novo Nordisk AS's net margin of --. Novo Nordisk AS's return on equity of 88.95% beat Viking Therapeutics's return on equity of --.

Novo Nordisk AS has a consensus price target of $117.14, signalling upside risk potential of 36.78%. On the other hand Viking Therapeutics has an analysts' consensus of $110.00 which suggests that it could grow by 170.94%. Given that Viking Therapeutics has higher upside potential than Novo Nordisk AS, analysts believe Viking Therapeutics is more attractive than Novo Nordisk AS.

Novo Nordisk AS has a beta of 0.447, which suggesting that the stock is 55.342% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.947, suggesting its less volatile than the S&P 500 by 5.344%.

Novo Nordisk AS has a quarterly dividend of $0.52 per share corresponding to a yield of 1.69%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk AS pays 37.96% of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novo Nordisk AS quarterly revenues are $10.5B, which are larger than Viking Therapeutics quarterly revenues of --. Novo Nordisk AS's net income of $4B is higher than Viking Therapeutics's net income of -$24.9M. Notably, Novo Nordisk AS's price-to-earnings ratio is 27.75x while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 9.72x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.